Cargando…
Galectin-3 inhibition as a potential therapeutic target in non-alcoholic steatohepatitis liver fibrosis
Nonalcoholic fatty liver disease continues to be one of the major health challenges facing the world, with estimates of non-alcoholic steatohepatitis (NASH) prevalence in over 25 percent of the world’s population. NASH represents a spectrum of disease that may lead to hepatic fibrosis and eventual c...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10011901/ https://www.ncbi.nlm.nih.gov/pubmed/36926236 http://dx.doi.org/10.4254/wjh.v15.i2.201 |
_version_ | 1784906503080116224 |
---|---|
author | Kram, Michael |
author_facet | Kram, Michael |
author_sort | Kram, Michael |
collection | PubMed |
description | Nonalcoholic fatty liver disease continues to be one of the major health challenges facing the world, with estimates of non-alcoholic steatohepatitis (NASH) prevalence in over 25 percent of the world’s population. NASH represents a spectrum of disease that may lead to hepatic fibrosis and eventual cirrhosis, with the risk of cirrhosis decompensation, and hepatocellular carcinoma. New therapies are desperately needed for NASH, especially for later stages of fibrosis and cirrhosis. Galectin-3 inhibition is being explored as a new liver antifibrotic therapy. This concise review will outline the state of the art of this new therapeutic target. |
format | Online Article Text |
id | pubmed-10011901 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Baishideng Publishing Group Inc |
record_format | MEDLINE/PubMed |
spelling | pubmed-100119012023-03-15 Galectin-3 inhibition as a potential therapeutic target in non-alcoholic steatohepatitis liver fibrosis Kram, Michael World J Hepatol Minireviews Nonalcoholic fatty liver disease continues to be one of the major health challenges facing the world, with estimates of non-alcoholic steatohepatitis (NASH) prevalence in over 25 percent of the world’s population. NASH represents a spectrum of disease that may lead to hepatic fibrosis and eventual cirrhosis, with the risk of cirrhosis decompensation, and hepatocellular carcinoma. New therapies are desperately needed for NASH, especially for later stages of fibrosis and cirrhosis. Galectin-3 inhibition is being explored as a new liver antifibrotic therapy. This concise review will outline the state of the art of this new therapeutic target. Baishideng Publishing Group Inc 2023-02-27 2023-02-27 /pmc/articles/PMC10011901/ /pubmed/36926236 http://dx.doi.org/10.4254/wjh.v15.i2.201 Text en ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. |
spellingShingle | Minireviews Kram, Michael Galectin-3 inhibition as a potential therapeutic target in non-alcoholic steatohepatitis liver fibrosis |
title | Galectin-3 inhibition as a potential therapeutic target in non-alcoholic steatohepatitis liver fibrosis |
title_full | Galectin-3 inhibition as a potential therapeutic target in non-alcoholic steatohepatitis liver fibrosis |
title_fullStr | Galectin-3 inhibition as a potential therapeutic target in non-alcoholic steatohepatitis liver fibrosis |
title_full_unstemmed | Galectin-3 inhibition as a potential therapeutic target in non-alcoholic steatohepatitis liver fibrosis |
title_short | Galectin-3 inhibition as a potential therapeutic target in non-alcoholic steatohepatitis liver fibrosis |
title_sort | galectin-3 inhibition as a potential therapeutic target in non-alcoholic steatohepatitis liver fibrosis |
topic | Minireviews |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10011901/ https://www.ncbi.nlm.nih.gov/pubmed/36926236 http://dx.doi.org/10.4254/wjh.v15.i2.201 |
work_keys_str_mv | AT krammichael galectin3inhibitionasapotentialtherapeutictargetinnonalcoholicsteatohepatitisliverfibrosis |